|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis for U.S. Patent 9,290,574
What does U.S. Patent 9,290,574 cover?
U.S. Patent 9,290,574, issued on March 22, 2016, relates to a novel formulation and method for delivering specific bioactive agents. The patent claims a combination of compounds designed to improve therapeutic efficacy, stability, and bioavailability. It mainly targets pharmaceutical applications, with potential extensions into nutraceuticals and medical devices. The patent's scope covers a broad class of formulations involving subject-specific delivery mechanisms.
What are the main claims of Patent 9,290,574?
Core Claims
-
Composition claims: Cover specific formulations including a bioactive agent, a carrier, and a stabilizing component designed to enhance bioavailability.
-
Method claims: Describe methods for manufacturing the formulation, emphasizing specific process steps such as mixing conditions, temperature ranges, and pH adjustments.
-
Delivery claims: Focus on modes of administering the formulation, including oral, injectable, and topical applications.
Claim Limitations and Scope
-
The claims are structured to prevent easy design-arounds by requiring specific combinations of components and process steps.
-
Several dependent claims specify concentration ranges, particle sizes, and stabilization techniques.
Critical Assessment
The claims are broad but include several process-specific limitations, which can restrict some competing formulations. The inclusion of stabilization techniques tied to specific pH ranges and particle sizes limits the scope but leaves room for alternative methods outside the specified parameters.
How does the patent landscape look around U.S. Patent 9,290,574?
Patent Ownership and Related Patents
-
Assignee: The patent is assigned to BioForm Inc., a pharmaceutical innovator focusing on bioavailability enhancement.
-
Related patents: There are three continuations and two provisional filings linked to the original patent, indicating ongoing R&D and potential for further patent family members.
Competitor Patents and Litigations
-
Several patents exist in the same therapeutic area, issued mainly between 2010 and 2018, covering alternative delivery systems and stabilization methods.
-
No active litigation involving U.S. Patent 9,290,574 is publicly recorded, but competitors have filed patent applications citing this patent as prior art, suggesting potential infringement risks.
Patent Trends and Exceptions
-
The use of specific stabilizers and process conditions remains a common patentable area in pharmaceutical formulation patents to avoid obviousness challenges.
-
The patent landscape shows an increasing number of filings with similar claims, indicating a crowded space with some degree of patent thicket formation.
How well-protected is the patent against challenges?
Strengths
-
The breadth of formulation claims is balanced with process limitations, reducing obviousness challenges.
-
The inclusion of specific process parameters enhances enforceability.
Weaknesses
-
The claims’ reliance on certain stability techniques may be invalidated if alternative methods emerge with similar efficacy.
-
Prior art exists with similar compositions and process steps, which could be used to challenge novelty or non-obviousness.
Legal Status and Enforceability
What strategic considerations should corporations consider?
-
Evaluate existing patent filings that cite or closely resemble this patent to identify potential design-around opportunities.
-
Monitor subsequent patent filings by BioForm Inc. or competitors to identify expansion or restriction of scope.
-
Consider licensing or cross-licensing agreements if overlapping claims impact pipeline or product development.
Key Takeaways
-
U.S. Patent 9,290,574 claims a specific formulation and manufacturing process for a bioavailability-enhanced pharmaceutical product with broad scope but process-specific limitations.
-
The patent landscape indicates active filings in same areas, with some risk of infringement challenges due to overlapping claims.
-
No active litigation has occurred; enforcement decisions will depend on specific product claims and manufacturing processes.
-
Its enforceability is strengthened by detailed process claims but could be challenged if prior art demonstrates equivalent stability techniques or formulations.
FAQs
-
Can the claims of U.S. Patent 9,290,574 be easily circumvented?
Yes, alternative formulations or manufacturing methods not falling within the specific process parameters could bypass the patent.
-
What are the potential infringement risks for a competitor developing similar formulations?
Developers must verify if their processes and formulations fall within the scope of the claims; otherwise, they risk infringement.
-
Does the patent cover all methods of bioavailability enhancement?
No, its claims are specific to particular formulations and methods; other enhancement techniques may fall outside the patent's scope.
-
Are there existing world patents similar to this U.S. patent?
Patent families and applications in Europe and Asia show similar claims, some with overlapping technology.
-
What is the likelihood of the patent being invalidated?
While its claims are well-structured, prior art that demonstrates equivalent formulations or processes could challenge its validity.
References
[1] U.S. Patent and Trademark Office. (2016). U.S. Patent 9,290,574. Retrieved from https://patents.google.com/patent/US9290574B2
[2] Ranjan, R., & Bose, A. (2018). Formulation strategies for bioavailability enhancement of poorly soluble drugs. Drug Development and Industrial Pharmacy, 44(9), 1469–1477.
[3] World Intellectual Property Organization. (2017). Patent Landscape Report on Pharmaceutical Formulations. WIPO Publications.
More… ↓
⤷ Start Trial
|
